📣 VC round data is live. Check it out!

Agilent Valuation Multiples

Discover Agilent's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Waters, Alcon, IDEXX Laboratories, Wuxi AppTec and more.

Agilent Overview

About Agilent

Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.


Founded

1999

HQ

United States

Employees

18.1K

Financials (LTM)

Revenue: $7B
EBITDA: $2B

EV

$40B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Agilent Financials

Agilent reported last 12-month revenue of $7B and EBITDA of $2B.

In the same LTM period, Agilent generated $4B in gross profit, $2B in EBITDA, and $2B in net income.

Revenue (LTM)


Agilent P&L

In the most recent fiscal year, Agilent reported revenue of $7B and EBITDA of $2B.

Agilent is profitable as of last fiscal year, with gross margin of 52%, EBITDA margin of 29%, and net margin of 23%.

See analyst estimates for Agilent
LTMLast FY202320242025202620272028
Revenue$7B$7B$7B$7B$7B
Gross Profit$4B$4B$3B$4B$4B
Gross Margin54%52%51%54%53%
EBITDA$2B$2B$2B$2B$2B
EBITDA Margin29%29%26%28%27%
EBIT Margin26%26%20%23%22%
Net Profit$2B$2B$1B$1B$1B
Net Margin23%23%18%20%20%
Net Debt-$2B---

Financial data powered by Morningstar, Inc.

Agilent Stock Performance

Agilent has current market cap of $38B, and enterprise value of $40B.

Market Cap Evolution


Agilent's stock price is $135.98.

Agilent share price increased by 0.3% in the last 30 days, and by 15.2% in the last year.

Agilent has an EPS (earnings per share) of $5.64.

See more trading valuation data for Agilent
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$40B$38B0.3%0.3%19.3%15.2%$5.64

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Agilent Valuation Multiples

Agilent trades at 5.6x EV/Revenue multiple, and 19.0x EV/EBITDA.

See NTM and 2027E valuation multiples for Agilent

EV / Revenue (LTM)


Agilent Financial Valuation Multiples

As of June 2, 2026, Agilent has market cap of $38B and EV of $40B.

Agilent has a P/E ratio of 23.1x.

LTMLast FY202320242025202620272028
EV/Revenue5.6x5.7x5.9x6.1x5.7x
EV/EBITDA19.0x20.0x23.0x21.4x21.1x
EV/EBIT21.1x22.5x29.1x26.9x25.6x
EV/Gross Profit10.3x11.0x11.5x11.2x10.8x
P/E23.1x24.1x30.7x29.7x28.0x
EV/FCF34.6x34.1x27.4x29.9x34.7x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Agilent Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Agilent Margins & Growth Rates

Agilent grew revenue by 7% and EBITDA by 9% in the last fiscal year.

In the most recent fiscal year, Agilent reported gross margin of 52%, EBITDA margin of 29%, and net margin of 23%.

See estimated margins and future growth rates for Agilent

Agilent Margins

Last FY202420252026202720282029
Gross Margin52%54%53%54%
EBITDA Margin29%28%27%29%
EBIT Margin26%23%22%27%
Net Margin23%20%20%23%
FCF Margin17%20%16%16%

Agilent Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth7%(3%)7%7%
Gross Profit Growth11%2%4%10%
EBITDA Growth9%8%1%17%
EBIT Growth11%8%5%28%
Net Profit Growth8%3%6%27%
FCF Growth(2%)(8%)(14%)7%

Data powered by FactSet, Inc. and Morningstar, Inc.

Agilent Operational KPIs

Agilent's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.

Agilent's Rule of 40 is 36% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Agilent's Rule of X is 47% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Agilent
LTMLast FY202320242025202620272028
Rule of 4036%36%---
Bessemer Rule of X47%47%---
Revenue per Employee-$0.4M---
Opex per Employee-$0.1M---
R&D Expenses to Revenue6%7%7%7%7%
Opex to Revenue-31%31%31%31%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Agilent Competitors

Agilent competitors include Waters, Alcon, IDEXX Laboratories, Wuxi AppTec, Natera, Siemens Healthineers, DexCom, GE HealthCare, ResMed and Mindray.

Most Agilent public comparables operate across Laboratory Services, Medical Devices, Medical Imaging & Diagnostics, BioTech, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Waters13.3x9.3x37.3x27.7x
Alcon3.4x3.4x13.3x13.0x
IDEXX Laboratories10.6x10.2x30.2x28.8x
Wuxi AppTec5.9x5.6x9.7x11.3x
Natera13.2x12.1x(138.3x)(129.7x)
Siemens Healthineers1.6x1.6x8.0x8.1x
DexCom6.0x5.7x20.5x19.0x
GE HealthCare1.8x1.7x9.7x9.9x

This data is available for Pro users. Sign up to see all Agilent competitors and their valuation data.

Start Free Trial

Acquisitions by Agilent

Agilent has acquired 21 companies to date.

Last acquisition by Agilent was on March 8th 2026. Agilent acquired Biocare Medical for $950M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Agilent

Biocare Medical
Sigsense Technologies
BioVectra
e-MSion
Description
-
Sigsense Technologies is a San Francisco-headquartered company offering an AI-powered platform for equipment management across industries. Its vendor-agnostic solution uses non-invasive IoT sensors to monitor power and environmental data from machine components. The AI analyzes this data to provide real-time performance metrics, overall equipment effectiveness scores, predictive maintenance alerts, and process optimization insights. Deployments span clinical labs, manufacturing, and other sectors reliant on machinery uptime.
BioVectra is a Charlottetown-headquartered contract development and manufacturing organization specializing in active pharmaceutical ingredients for biotechnology and pharmaceutical companies worldwide. The company excels in synthetic organic chemistry, microbial fermentation, and biologics production for treatments targeting cancer, kidney disease, and cardiovascular conditions. Founded in 1970, BioVectra operates cGMP facilities in Canada and India, offering services from process development to commercial-scale manufacturing of complex molecules including PEGylated conjugates.
e-MSion is a developer of electron capture dissociation technology for mass spectrometry in life sciences research. The U.S.-based company enhances protein and peptide analysis for proteomics, biopharma, and structural biology applications.
HQ CountryPhilippinesUnited StatesCanadaUnited States
HQ City
-
San Francisco, CA
Charlottetown
Corvallis, OR
Deal Date8 Mar 202629 Jul 202422 Jul 20249 Mar 2023
Valuation$950Mundisclosed$925Mundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Agilent acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Agilent

Agilent has invested in 18 companies to date.

Latest investment by Agilent was on June 27th 2024. Agilent invested in RareCyte in their $20M Undisclosed stage round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Agilent

RareCyte
Elegen
Biofidelity
Halo X Ray Technologies
Description
RareCyte is a Seattle-based provider of precision biology platforms for spatial analysis and liquid biopsy. Its Orion suite includes imaging systems and multiplexed panels for tissue biomarker studies in oncology research. The AccuCyte system prepares samples for CyteFinder instruments that detect and characterize circulating tumor cells using RarePlex kits. Services cover assay development, clinical trial testing, and data analytics for pharmaceutical partners.
Elegen is a San Carlos, California-headquartered biotech company pioneering microfluidic DNA synthesis. Founded in 2017, it develops high-throughput synthesizers producing long, high-fidelity oligonucleotides for gene editing and therapeutics. Elegen partners with pharmaceutical firms to accelerate synthetic biology applications.
Biofidelity is a Cambridge, England-headquartered molecular diagnostics company founded in 2019. It offers the GoHealth assay for ultra-rapid PCR detection of DNA targets in under 20 minutes without nucleic acid extraction. Biofidelity's platform supports point-of-care testing in oncology, infectious diseases, prenatal screening, and transplant monitoring across Europe and North America.
Halo X Ray Technologies is a Nottingham-based developer of OEM X-ray diffraction systems using patented Focal Construct Technology for aviation security and medical imaging markets. Spun out from Nottingham Trent University and Cranfield Forensic Institute, the company builds on prior innovations like divergent beam X-ray tech licensed to 3DX-RAY and kinetic depth systems marketed via Astrophysics Inc. HALO solutions target explosives detection in airports and point-of-care fracture risk prediction through an EPSRC-funded consortium. Operations emphasize platform versatility across security and healthcare applications.
HQ CountryUnited StatesUnited StatesUnited KingdomUnited Kingdom
HQ City
Seattle, WA
San Francisco, CA
Cambridge
Nottingham
Deal Date27 Jun 202414 May 20243 Apr 20246 Sep 2023
RoundUndisclosed stageSeries BUndisclosed stageSeries A
Raised$20M$35M$24M$2M
Investors5AM Ventures; Agilent; Arboretum Ventures; F-Prime; GKCC; HealthQuest Capital; Ron Seubert; Sheatree Capital; The Forest Road Company8VC; ACVC Partners; Agilent; Alix Ventures; AME Cloud Ventures; Andreessen Horowitz; Digitalis Ventures; GSK; John Ballantyne; KdT Ventures; Triatomic CapitalAgilent; BlueYard Capital; Longwall Venture; Octopus VenturesAgilent; Future Planet Capital
Valuationundisclosed$100Mundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Agilent investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Agilent

When was Agilent founded?Agilent was founded in 1999.
Where is Agilent headquartered?Agilent is headquartered in United States.
How many employees does Agilent have?As of today, Agilent has over 18K employees.
Who is the CEO of Agilent?Agilent's CEO is Padraig McDonnell.
Is Agilent publicly listed?Yes, Agilent is a public company listed on NYSE.
What is the stock symbol of Agilent?Agilent trades under A ticker.
When did Agilent go public?Agilent went public in 1999.
Who are competitors of Agilent?Agilent main competitors include Waters, Alcon, IDEXX Laboratories, Wuxi AppTec, Natera, Siemens Healthineers, DexCom, GE HealthCare, ResMed, Mindray.
What is the current market cap of Agilent?Agilent's current market cap is $38B.
What is the current revenue of Agilent?Agilent's last 12 months revenue is $7B.
What is the current revenue growth of Agilent?Agilent revenue growth (NTM/LTM) is 7%.
What is the current EV/Revenue multiple of Agilent?Current revenue multiple of Agilent is 5.6x.
What is the current EBITDA of Agilent?Agilent's last 12 months EBITDA is $2B.
What is Agilent's EBITDA margin?Agilent's last 12 months EBITDA margin is 29%.
What is the current EV/EBITDA multiple of Agilent?Current EBITDA multiple of Agilent is 19.0x.
What is the current FCF of Agilent?Agilent's last 12 months FCF is $1B.
What is Agilent's FCF margin?Agilent's last 12 months FCF margin is 16%.
What is the current EV/FCF multiple of Agilent?Current FCF multiple of Agilent is 34.6x.
How many companies Agilent has acquired to date?As of June 2026, Agilent has acquired 21 companies.
What was the largest acquisition by Agilent?$1B acquisition of BioTek Instruments on 11th July 2019 was the largest M&A Agilent has done to date.
What companies Agilent acquired?Agilent acquired BioTek Instruments, Biocare Medical, BioVectra, Resolution Bioscience, Advanced Analytical Technologies, ACEA BIO, Seahorse Bioscience, Lasergen, Multiplicom, Cartagenia, and 11 other companies.
In how many companies Agilent has invested to date?As of June 2026, Agilent has invested in 18 companies.
In what companies Agilent invested in?Agilent invested in Lasergen, Mobilion Systems, DNA Script, Elegen, Mission Bio, Purigen Biosystems, Molecular Assemblies, RareCyte, Biofidelity, Gen9, Akadeum Life Sciences, Nicoya Lifesciences, PreciseDx, NanoCellect Biomedical, Cardea Bio, Arima Genomics, Halo Labs, and Halo X Ray Technologies.

See public comps similar to Agilent

Lists including Agilent

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial